TrialCancer2020

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.

Maria M Rubinstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.